-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A study led by Dr.
Camidge said that significant progress has been made in the treatment of non-small cell lung cancer.
"We are beginning to realize that non-small cell lung cancer is more than just a disease," Camidge said
Gene amplification becomes a driving factor for cancer
This new paper titled "Crizotinib in Patients With MET-Amplified NSCLC" was published in the Journal of Thoracic Oncology and introduced the third method of defining NSCLC subgroups
"Unlike gene mutations or gene rearrangements-either present or not-gene amplification is a constant variable," Camidge said
In this Pfizer-sponsored study, Camidge and other researchers paid special attention to MET amplification
Theoretically, if MET expansion is a driving factor in some patients with non-small cell lung cancer, inhibition of MET can slow or prevent disease progression in these patients
During the study period, a total of 88 patients with different levels of MET amplification were treated with crizotinib
The results showed that patients with the highest level of MET amplification had the highest response rate to crizotinib treatment and longer survival without tumor progression, while patients with lower levels of MET amplification had a poorer response to treatment
Camidge said: "For this rare subtype of lung cancer, this is a long and difficult process, but I think this is a good evidence that some patients only cause cancer because of MET amplification
Detection and treatment for MET amplification
Camidge said there are many reasons why non-small cell lung cancer driven by MET expansion is unique
If lung cancer occurs in young people and people who have never smoked, doctors will associate cancer with oncogenes
Because of this, Camidge believes that patients with non-small cell lung cancer without a confirmed driver gene should consider MET amplification testing
As for the use of MET inhibitors to treat patients with non-small cell lung cancer driven by MET expansion, Camidge said that pharmaceutical companies have begun to explore MET expansion as an additional target for new and existing MET inhibitors
"This is a truly actionable oncogene," he said
.
"It's rare, but it's real
.
"
###
Crizotinib in Patients With MET-Amplified NSCLC
https://doi.
org/10.
1016/j.
jtho.
2021.
02.
010